Prothena Q4 2023 net loss $67.5M; cash $621M; guides 2024 cash burn ~$208-225M

PROTHENA CORP PUBLIC LTD CO

2023-FY EPS reported -$2.76 revenue$91,370,000

Net loss Q4 $67.5M ($1.26 loss per share) vs net income $6.3M Q4 2022; full year loss $147.0M.
Total revenue Q4 $0.3M (vs $49.9M Q4 2022); full year $91.4M including $55M BMS milestone.
Cash, equivalents & restricted cash $621M at Dec 31, 2023; no debt. 2024 cash use guidance $208-225M.
Phase 1 PRX012 (Alzheimer's) data update expected 2024; partner BMS to advance BMS-986446 to Phase 2 in 1H2024.
AFFIRM-AL birtamimab topline (Mayo Stage IV AL amyloidosis) expected between 4Q2024-2Q2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PROTHENA CORP PUBLIC LTD CO updated its the fourth quarter and fiscal year ended December 31, 2023 guidance (initiated).

Period: the fourth quarter and fiscal year ended December 31, 2023
Guidance: initiated
Result: reported results

Exact text from the filing

On February 15, 2024, Prothena Corporation plc issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

PROTHENA CORP PUBLIC LTD CO filing history →

Source: SEC EDGAR

accession 0001559053-24-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.